Digital Health

99 VCs and 35 funds investing in Digital Health

VCs investing in Digital Health

Bryan Rosenblatt

Venture Partner

88%

Craft Ventures

Check: No personal check-size range is published. Craft invests from angel/seed through venture and growth; amounts in Bryan's investment announcements are total company rounds, not his personal or standard Craft checks.

Bryan applies a growth, revenue, and marketplace lens shaped by building Reddit's New York revenue organization and Twitter's startup advertising business. His investments favor products that remove expensive operational friction, demonstrate clear founder-market fit, delight customers enough to produce strong advocacy, and can use software, AI, services, or community-led distribution to create a meaningful performance advantage.

AngelPre-SeedSeed

Alex Morgan

Partner

88%

Khosla Ventures

Check: No personal check range is published. Khosla's Seed Fund supports science and business-model experiments, historically often with roughly $1M–$2M according to a 2020 firm interview, while its Main Fund covers early through later stages. These are firm-level references, not Alex's authority.

Alex invests where computation, biology, and healthcare converge. His scientific and clinical background supports a systems view of biomarker discovery, therapeutics, diagnostics, personalized medicine, neurotechnology, connected devices, and AI-enabled care. He favors important health outcomes and technologies that can automate expensive or inconsistent processes, increase access, and create reproducible, lower-cost care—not science detached from delivery and economics.

IncubationPre-SeedSeed

Jun Wakabayashi

Venture Principal

88%

AppWorks

Check: Not publicly disclosed for Beacon Funds commitments. AppWorks' direct-company strategy publishes US$200K to US$15M per deal from Seed through Series C; that range should not be applied to Jun's venture-fund investments.

Jun uses fund investments as ecosystem infrastructure: back locally connected or specialist managers, exchange market intelligence and diligence, create co-investment and follow-on capital paths, and help portfolio companies enter new Asian markets. In direct opportunities, his writing favors repeat founders with learned resilience, large problems native to Southeast Asia, sound unit economics, profitability and margin discipline, and teams able to adapt when the original model fails.

Emerging ManagersVenture FundsSeed

Arielle Rothman

Investor

87%

BoxGroup

Check: No reliable Arielle-specific check size is public. BoxGroup describes itself as an earliest-stage investor, but founders should confirm current round fit and allocation directly rather than relying on third-party range estimates.

Arielle invests within BoxGroup's broad earliest-stage mandate. Her differentiated documented context is technical and translational: Harvard bioengineering research, founding a postpartum medical-device project, product work in fertility AI and neuromodulation, mechanical engineering at a bioelectronic-medicine startup, and consulting at BCG. This supports a credible ability to evaluate user need, clinical workflow, product design, manufacturing, regulatory planning and commercialization in technical health businesses. It does not establish an exclusive healthcare mandate or a personally published investment thesis.

Pre-seedSeedEarliest-stage company formation

Jackie Vullinghs

Partner

84%

AirTree Ventures (Web3)

Check: Neither Airtree nor Jackie publishes her personal check range or decision authority. The firm is seed-first and supports companies through later stages; individual portfolio round totals do not reveal Airtree's allocation or Jackie's authority.

Jackie backs Australia and New Zealand founders from very early product formation through scale. Her disclosed portfolio crosses AI and enterprise software, healthcare, fintech, consumer platforms, future-of-work tools, commerce, and purpose-led brands. Her investment notes repeatedly test market size and structural change, founder intensity and fit, customer love, defensible unit economics, resilience, and the ability to convert an initial wedge into a global company.

Pre-SeedSeedSeries A

Fanis Tsarouchis

Senior Principal

83%

Big Pi Ventures

Check: Growth-fund level: Big Pi Growth I states that it leads with €7M–€20M+ per company. Big Pi's overall platform spans €0.5M–€30M across funds. Neither range is published as Fanis's personal allocation authority.

Fanis supports European technology scale-ups moving toward market leadership with growth capital plus operational and financial expertise. His background in TMT investment banking and as FlexCar's finance leader supports a value-creation lens centered on financing structure, valuation, capital efficiency, international expansion, organic growth, and selective M&A rather than capital alone.

Series BSeries CGrowth Equity

Wendy Xiao

Partner

83%

Northzone (Web3)

Check: Not publicly disclosed. Northzone states that the firm invests from Seed through Growth and can remain a partner through pre-IPO; Wendy's current profile labels her personal focus as Early and says she likes to work with founders from as early as seed.

Wendy backs companies that change consumer behavior and expand the economic pie by capturing neglected externalities. She studies technology through people and behavior change, looking for a valuable position in a shifting value chain and a product capable of profound systemic change. Her hypothesis-led process separates factual and emotional evidence, makes assumptions explicit, challenges them through diligence, and still requires a differentiated leap of faith about fund-returning potential.

SeedSeries AEarly Stage

Panos Metsis

Partner

82%

Big Pi Ventures

Check: Growth-fund level: Big Pi Growth I states that it leads with €7M–€20M+ per company. Panos focuses on Series B+ growth investments; the published fund range is not a guarantee of his personal allocation authority for any deal.

Panos leads growth investments in European technology companies that already show category leadership and can use €7M–€20M+ plus active operating support to scale internationally. His recent work emphasizes InfraTech and Physical AI at the intersection of innovative technology and real infrastructure, where proprietary systems, strong customer ROI, global deployments, and Southeast European operating hubs can create durable scale advantages.

Series BSeries CGrowth Equity

Shelly Lanning

Venture Partner

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Shelly Lanning invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

Jenni Le

Principal

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Jenni Le invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

John Neis

Partner

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

John Neis invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

Joslin Owens

Director of Finance

80%

7wire Ventures

Check: 7wire Ventures does not publish a standard current check-size range on its official site.

Joslin Owens is listed in a Director of Finance capacity at 7wire Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedSeries A

Cheryl R. Blanchard, PhD

Executive in Residence

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Cheryl R. Blanchard, PhD invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

Margaret Kaczor Andrew

Venture Partner

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Margaret Kaczor Andrew invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

Becky Hoerman

Controller

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Becky Hoerman is listed in a Controller capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.

SeedEarly StageGrowth

Ravi Varma

Venture Partner

80%

Tau Ventures

Check: Tau Ventures does not publish a standard current check-size range on its live official site.

Ravi Varma invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.

Pre-SeedSeedGrowth

Gary Ang

Venture Partner

80%

Tau Ventures

Check: Tau Ventures does not publish a standard current check-size range on its live official site.

Gary Ang invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.

Pre-SeedSeedGrowth

Sharon Huang

Principal

80%

Tau Ventures

Check: Tau Ventures does not publish a standard current check-size range on its live official site.

Sharon Huang invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.

Pre-SeedSeedGrowth

Larry Augustin

Venture Partner

80%

Tau Ventures

Check: Tau Ventures does not publish a standard current check-size range on its live official site.

Larry Augustin invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.

Pre-SeedSeedGrowth

Bruce Broussard

Venture Partner

80%

Define Ventures

Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.

Bruce Broussard invests or supports investments through Define Ventures's published strategy: Back category-defining healthcare companies that combine deep ecosystem understanding with a technology-driven mindset across enterprise, value-based care and consumer health.

IncubationSeedSeries A

David Schonthal

Operating Partner

80%

7wire Ventures

Check: 7wire Ventures does not publish a standard current check-size range on its official site.

David Schonthal is listed in a Operating Partner capacity at 7wire Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedSeries A

Scott Button

Partner

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Scott Button invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

David Arnstein

Partner and Chief Financial Officer

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

David Arnstein is listed in a Partner and Chief Financial Officer capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.

SeedEarly StageGrowth

Karsten Vagner

Head of People

80%

Define Ventures

Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.

Karsten Vagner is listed in a Head of People capacity at Define Ventures. This profile preserves that functional distinction; the firm's investment mandate is included only as shared context.

IncubationSeedSeries A

Joe Amaral, MD

Chief Medical and Scientific Officer

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Joe Amaral, MD is listed in a Chief Medical and Scientific Officer capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.

SeedEarly StageGrowth

Katharine Morris

Administrative Assistant & Office Manager

80%

Define Ventures

Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.

Katharine Morris is listed in a Administrative Assistant & Office Manager capacity at Define Ventures. This profile preserves that functional distinction; the firm's investment mandate is included only as shared context.

IncubationSeedSeries A

Sathya Shanthakumar

Director of Investor Relations

80%

7wire Ventures

Check: 7wire Ventures does not publish a standard current check-size range on its official site.

Sathya Shanthakumar is listed in a Director of Investor Relations capacity at 7wire Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedSeries A

Vivek Ranadivé

Founder and Managing Director

80%

Bow Capital

Check: $5M average investment into core companies, as published by Bow Capital.

Vivek Ranadivé is listed in a Founder and Managing Director capacity at Bow Capital. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

SeedSeries A

Disha Karale

Investor

80%

BoxGroup

Check: BoxGroup publicly invests up to $1M. Third-party profiles estimate Disha's range at $500K–$1M, but no primary source confirms a personal range, so the firm ceiling is the safer planning assumption.

Disha invests at the earliest stages with a differentiated mix of finance, neuroscience, biotech R&D, and prior growth-investing exposure. Her public investor profile points to AI, enterprise infrastructure and software, digital and consumer health, biotech, and commerce. Within BoxGroup's generalist model, the through-line is an exceptional founder using technical or domain insight to create a category, not a rigid sector checklist.

Pre-SeedSeedSeries A

Sonal Panda

Advisory Partner

80%

Tau Ventures

Check: Tau Ventures does not publish a standard current check-size range on its live official site.

Sonal Panda is listed in a Advisory Partner capacity at Tau Ventures. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.

Pre-SeedSeedGrowth

Amit Garg

Founding Partner

80%

Tau Ventures

Check: Tau Ventures does not publish a standard current check-size range on its live official site.

Amit Garg invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.

Pre-SeedSeedGrowth

Emma Merrick

Associate

80%

HealthX Ventures

Check: HealthX Ventures does not publish a standard check-size range on its current official website.

Emma Merrick contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.

Pre-RevenueSeedEarly Stage

Fahad Qureshi

Vice President, Accounting and Finance

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Fahad Qureshi is listed in a Vice President, Accounting and Finance capacity at OCA Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

SeedSeries ASeries B

Dan Neill

Venture Consultant

80%

HealthX Ventures

Check: HealthX Ventures does not publish a standard check-size range on its current official website.

Dan Neill contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.

Pre-RevenueSeedEarly Stage

Sanjay Rao

Founding Partner

80%

Tau Ventures

Check: Tau Ventures does not publish a standard current check-size range on its live official site.

Sanjay Rao invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.

Pre-SeedSeedGrowth

Adina Davis

Partner

80%

BoxGroup

Check: BoxGroup publicly invests up to $1M. Older third-party profiles place Adina's typical early-stage range around $250K–$500K, but founders should treat the firm's current $1M ceiling—not an old personal range—as authoritative.

Adina is an early-stage generalist with a publicly documented emphasis on B2B software, consumer internet, and fintech. Her operating background in e-commerce and recent visible interest in AI deployment and software agents point to companies that convert new technical capability into practical workflows. She invests within BoxGroup's people-first formation-stage model, prioritizing founder-market fit and category potential over polished early metrics.

Pre-SeedSeedSeries A

Sam Bogrov

Principal

80%

Tau Ventures

Check: Tau Ventures does not publish a standard current check-size range on its live official site.

Sam Bogrov invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.

Pre-SeedSeedGrowth

Stefano Guidotti

Partner

80%

P101

Check: P101 does not publish one standard current check-size range on its official site.

Stefano Guidotti invests or supports investment work through P101. P101's published strategy is to partner early and for the long term with bold, resilient founders building technology companies that can matter internationally..

SeedSeries AEarly Growth

Laura Hilty

Principal

80%

HealthX Ventures

Check: HealthX Ventures does not publish a standard check-size range on its current official website.

Laura Hilty contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.

Pre-RevenueSeedEarly Stage

Roy Rosin

Board Partner

80%

First Round Capital

Check: Firm-level: First Round says initial investments typically range from $1M-$7M, average about $3.5M, and have ranged below and above that; participating rounds have ranged from $100K-$20M.

Roy spends most of his First Round time in healthcare, applying three decades of product, innovation, and care-delivery experience to companies that can materially improve lives. He favors practical experimentation and measurable implementation over technology theater: identify a consequential workflow, build with the private context and orchestration required for accuracy, rigorously test real outcomes, and help founders win early customers, prioritize development, refine sales, hire, and learn faster.

Pre-SeedSeed

Lynne Chou O'Keefe

Founder & Managing Partner

80%

Define Ventures

Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.

Lynne Chou O'Keefe invests or supports investments through Define Ventures's published strategy: Back category-defining healthcare companies that combine deep ecosystem understanding with a technology-driven mindset across enterprise, value-based care and consumer health.

IncubationSeedSeries A

Tejas Vijh

Associate

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Tejas Vijh invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

Frank Williams

Venture Partner

80%

Define Ventures

Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.

Frank Williams invests or supports investments through Define Ventures's published strategy: Back category-defining healthcare companies that combine deep ecosystem understanding with a technology-driven mindset across enterprise, value-based care and consumer health.

IncubationSeedSeries A

Carolyn Magill

Venture Partner

80%

Define Ventures

Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.

Carolyn Magill invests or supports investments through Define Ventures's published strategy: Back category-defining healthcare companies that combine deep ecosystem understanding with a technology-driven mindset across enterprise, value-based care and consumer health.

IncubationSeedSeries A

Tom Richards

Operating Partner

80%

7wire Ventures

Check: 7wire Ventures does not publish a standard current check-size range on its official site.

Tom Richards is listed in a Operating Partner capacity at 7wire Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedSeries A

Liz Todia Zambory

Principal

80%

Mutual Capital Partners

Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.

Liz Todia Zambory invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.

Early StageGrowth

Alexis Johnson

Chief of Staff

80%

HealthX Ventures

Check: HealthX Ventures does not publish a standard check-size range on its current official website.

Alexis Johnson contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.

Pre-RevenueSeedEarly Stage

Claire Smilow

Partner

80%

BoxGroup

Check: BoxGroup publicly invests up to $1M. Some third-party directories show an older $250K–$500K personal range, but no current primary source confirms a separate personal allocation.

Claire backs formation-stage technology companies as a BoxGroup generalist, with visible strength across enterprise and developer software, AI-native products, consumer experiences, and marketplaces. Her operating and investing background supports a product-and-distribution lens: founders should pair a distinctive experience with a credible route to repeated use and category leadership, even when the company is still pre-product or pre-traction.

Pre-SeedSeedSeries A

Paul Weiss

Partner

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Paul Weiss invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

Brian Lindstrom

Partner

80%

HealthX Ventures

Check: HealthX Ventures does not publish a standard check-size range on its current official website.

Brian Lindstrom contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.

Pre-RevenueSeedEarly Stage

Shannon Knous

VP of Finance & Operations

80%

Define Ventures

Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.

Shannon Knous is listed in a VP of Finance & Operations capacity at Define Ventures. This profile preserves that functional distinction; the firm's investment mandate is included only as shared context.

IncubationSeedSeries A

Lauren O'Mahony

Head of Marketing

80%

Define Ventures

Check: Define Ventures does not publish a standard current check-size range; it reports six funds and $800M under management.

Lauren O'Mahony is listed in a Head of Marketing capacity at Define Ventures. This profile preserves that functional distinction; the firm's investment mandate is included only as shared context.

IncubationSeedSeries A

Cameron Raglin

Senior Associate

80%

7wire Ventures

Check: 7wire Ventures does not publish a standard current check-size range on its official site.

Cameron Raglin invests or supports investments through 7wire Ventures's published strategy: Build and back early-stage digital-health companies that give informed, connected consumers more control and improve healthcare quality, access, outcomes and cost.

Pre-SeedSeedSeries A

Allison Weiland

Finance and Operations Manager

80%

Tamarind Hill

Check: $2M-$7M seed rounds, as published by Tamarind Hill.

Allison Weiland is listed in a Finance and Operations Manager capacity at Tamarind Hill. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

SeedEarly Stage

Glenda Grazioli

Partner

80%

P101

Check: P101 does not publish one standard current check-size range on its official site.

Glenda Grazioli invests or supports investment work through P101. P101's published strategy is to partner early and for the long term with bold, resilient founders building technology companies that can matter internationally..

SeedSeries AEarly Growth

Alex Shandiz

General Partner

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Alex Shandiz invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

Ariel MacTavish

Venture Partner

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Ariel MacTavish invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

Audrey Beckman

Partner and Chief Innovation Officer

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Audrey Beckman invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

Dick Aderman

Studio Director

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Dick Aderman is listed in a Studio Director capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedSeries A

Oscar Moralez

Founder and Managing Partner

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Oscar Moralez invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

Todd R. Lugar

Controller and HR Lead

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Todd R. Lugar is listed in a Controller and HR Lead capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedSeries A

Shannon Flaherty

VP, Operations & Compliance

80%

HealthX Ventures

Check: HealthX Ventures does not publish a standard check-size range on its current official website.

Shannon Flaherty contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.

Pre-RevenueSeedEarly Stage

Christie Currie

Senior Associate

80%

Tamarind Hill

Check: $2M-$7M seed rounds, as published by Tamarind Hill.

Christie Currie invests or supports investments through Tamarind Hill's published strategy: Lead seed rounds for B2B healthcare companies with early product-market fit across decentralized care, care economics and healthcare supply-chain innovation.

SeedEarly Stage

Josh Buehler

Operating Partner

80%

Tamarind Hill

Check: $2M-$7M seed rounds, as published by Tamarind Hill.

Josh Buehler invests or supports investments through Tamarind Hill's published strategy: Lead seed rounds for B2B healthcare companies with early product-market fit across decentralized care, care economics and healthcare supply-chain innovation.

SeedEarly Stage

Ben Trumbull

Managing Partner

80%

Tamarind Hill

Check: $2M-$7M seed rounds, as published by Tamarind Hill.

Ben Trumbull invests or supports investments through Tamarind Hill's published strategy: Lead seed rounds for B2B healthcare companies with early product-market fit across decentralized care, care economics and healthcare supply-chain innovation.

SeedEarly Stage

Tony Petrucciani

Partner and Chief Financial Officer

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Tony Petrucciani is listed in a Partner and Chief Financial Officer capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedSeries A

Bob Saunders

General Partner

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Bob Saunders invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

Nick Schoewe

Vice Chairman and General Partner

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Nick Schoewe invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

Kevin McQuillan

General Partner

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Kevin McQuillan invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

Murray Rode

General Partner

80%

Bow Capital

Check: $5M average investment into core companies, as published by Bow Capital.

Murray Rode invests or supports investments through Bow Capital's published strategy: Back founders building AI for the physical world across modern industry, defense, logistics and digital biology, using the University of California ecosystem to accelerate science into society.

SeedSeries A

Michelle Cao

Vice President, Investments

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Michelle Cao invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

Manu Sharma

Vice President, Investments

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Manu Sharma invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

Kelley Quinn

Finance and Operations Manager

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Kelley Quinn is listed in a Finance and Operations Manager capacity at OCA Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

SeedSeries ASeries B

Waverly Deutsch

Operating Partner

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Waverly Deutsch invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

Peter Ianlo

Chairman and Co-Founder

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Peter Ianlo invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

Sarah Manasevit

Senior Associate

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Sarah Manasevit invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

Leticia Martinez

Senior Executive Assistant

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Leticia Martinez is listed in a Senior Executive Assistant capacity at OCA Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

SeedSeries ASeries B

Kayla Liederbach

Fractional Head of Marketing

80%

HealthX Ventures

Check: HealthX Ventures does not publish a standard check-size range on its current official website.

Kayla Liederbach contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.

Pre-RevenueSeedEarly Stage

Bill Trainor

Co-Founder and Partner

80%

Mutual Capital Partners

Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.

Bill Trainor invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.

Early StageGrowth

Wayne Wallace

Co-Founder and Partner

80%

Mutual Capital Partners

Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.

Wayne Wallace invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.

Early StageGrowth

Ally Thill

Project Leader

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Ally Thill is listed in a Project Leader capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedSeries A

Ian Drury

Venture Partner

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Ian Drury invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

Dan Clark

Venture Partner

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Dan Clark invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

David Helmer

Partner

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

David Helmer invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

Eric Beier

Partner and Chief Medical Officer

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Eric Beier invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

Insoo Chang

Principal

80%

Tau Ventures

Check: Tau Ventures does not publish a standard current check-size range on its live official site.

Insoo Chang invests or supports investments through Tau Ventures's published strategy: Partner early with founders applying AI to healthcare, enterprise workflows, automation and frontier technologies, with selective support through growth.

Pre-SeedSeedGrowth

Mark Shary

Managing Partner

80%

Tamarind Hill

Check: $2M-$7M seed rounds, as published by Tamarind Hill.

Mark Shary invests or supports investments through Tamarind Hill's published strategy: Lead seed rounds for B2B healthcare companies with early product-market fit across decentralized care, care economics and healthcare supply-chain innovation.

SeedEarly Stage

Jim Dugan

Founding Managing Partner

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Jim Dugan invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

Steve Shein

Principal

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Steve Shein invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

John Dugan

Chairman Emeritus and Co-Founder

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

John Dugan invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

Dave Zyer

Venture Partner

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Dave Zyer invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

John Barnard

MBA Intern

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

John Barnard invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

Rashika Rahman

Intern

80%

OCA Ventures

Check: $1M-$3M with follow-on capacity, as published by OCA Ventures.

Rashika Rahman invests or supports investments through OCA Ventures's published strategy: Invest in U.S. and Canadian companies with dramatic growth potential, launched products and measurable early customer adoption.

SeedSeries ASeries B

Jim Adox

Managing Partner

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Jim Adox invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

Will Brune

Senior Associate

80%

Mutual Capital Partners

Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.

Will Brune invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.

Early StageGrowth

Mark Bakken

Managing Partner

80%

HealthX Ventures

Check: HealthX Ventures does not publish a standard check-size range on its current official website.

Mark Bakken contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.

Pre-RevenueSeedEarly Stage

Samantha McGrandy

Chief Financial Officer

80%

HealthX Ventures

Check: HealthX Ventures does not publish a standard check-size range on its current official website.

Samantha McGrandy contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.

Pre-RevenueSeedEarly Stage

Darcey Nett

Partner

80%

HealthX Ventures

Check: HealthX Ventures does not publish a standard check-size range on its current official website.

Darcey Nett contributes to HealthX Ventures's published strategy: Lead seed equity rounds in scalable digital-health companies and actively help with healthcare customers, teams, operations and syndicates.

Pre-RevenueSeedEarly Stage

Linda Olson

Office Manager

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Linda Olson is listed in a Office Manager capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.

SeedEarly StageGrowth

Funds focused on Digital Health

EquityPitcher Ventures

Zürich, Switzerland

44 people0 investments

NLC Health Ventures

Amsterdam, Netherlands

37 people0 investments

Seventure Partners

Paris, France

36 people0 investments

Innovestor

Helsinki, Finland

28 people0 investments

Ventech

Paris, Helsinki, Stockholm, Munich, Hong Kong and Shanghai

28 people0 investments

P101

Milan, Italy

24 people0 investments

Wellington Partners

Munich, Germany

23 people0 investments

Kurma Partners

Paris, France / Munich, Germany

22 people0 investments

OCA Ventures

Chicago, Illinois

18 people0 investments

Capnamic

Cologne and Berlin, Germany

16 people0 investments

HPE Growth

Amsterdam, Netherlands

16 people0 investments

nFront Ventures

Oslo, Norway and London, United Kingdom

15 people0 investments

3VC

Vienna, Austria

14 people0 investments

Define Ventures

Silicon Valley, California

14 people0 investments

Calm/Storm Ventures

Vienna, Austria

14 people0 investments

Panakès Partners

Milan, Italy

14 people0 investments

7wire Ventures

Chicago, Illinois

12 people0 investments

Boomerang Ventures

Indianapolis, Indiana

12 people0 investments

Clarevia

Madison, Wisconsin

12 people0 investments

GoHub Ventures

Valencia, Spain

12 people0 investments

Nina Capital

Barcelona, Spain

11 people0 investments

Heal Capital

Berlin, Germany

11 people0 investments

HealthX Ventures

Madison, Wisconsin

10 people0 investments

Tau Ventures

Palo Alto, California

AUM: $85M+ AUM disclosed on the firm's archived official site

9 people0 investments

Genesis Ventures

Athens, Greece

9 people0 investments

Bow Capital

Menlo Park, California

8 people0 investments

People Ventures

Copenhagen, Denmark

8 people0 investments

TEN13

Brisbane, Australia

8 people0 investments

Zero One Hundred

Bratislava, Prague, Cyprus and the UAE

8 people0 investments

Vesalius Biocapital

Luxembourg

5 people0 investments

Mutual Capital Partners

Westlake, Ohio

4 people0 investments

Rock Health Capital

San Francisco, California

5 people0 investments

Tamarind Hill

Dublin, Ohio

5 people0 investments

Healthy.Capital

Amsterdam, Netherlands

4 people0 investments

GreyMatter

United States

4 people0 investments